What I have: Medutest · retatrutide.
I can find plenty of assertions about this and almost no reasoning, which is usually a sign that nobody has checked.
Assume no laboratory access beyond what I can pay a third party for.
Concretely, what should I do, and how would I know afterwards whether I did it right?
Batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.
Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.
| Component | Typical share | Counted in purity? | Counted in content? |
|---|---|---|---|
| Target peptide | 88–94 % | Yes, as main peak | Yes |
| Related impurities | 1–3 % | Yes, as other peaks | No |
| Counter-ion (TFA or acetate) | 2–8 % | No | No |
| Residual water | 2–6 % | No | No |
| Bulking agent, if present | 0–40 % | No | No |
If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.
Assume segregation is possible, and design your sampling to catch it if it exists.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsThe single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.
If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.
Put another way, the sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.
If testing multiple vials, state how many you tested and why you chose those vials.
edited 23 Oct 2024 by a_lindgren — removed a claim I could not source
Worth being precise here: thermal history during shipping is different for every vial, so a lot that experienced thermal abuse may have internal variation even if it was originally homogeneous.
A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.
Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
If a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.
Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
Worth being precise here: most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.
If the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.